+

HK40071349A - Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody - Google Patents

Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody Download PDF

Info

Publication number
HK40071349A
HK40071349A HK62022061147.4A HK62022061147A HK40071349A HK 40071349 A HK40071349 A HK 40071349A HK 62022061147 A HK62022061147 A HK 62022061147A HK 40071349 A HK40071349 A HK 40071349A
Authority
HK
Hong Kong
Prior art keywords
lag
administration
bispecific antibody
dosage regimes
regimes
Prior art date
Application number
HK62022061147.4A
Other languages
Chinese (zh)
Inventor
Michelle Morrow
Fiona GERMASCHEWSKI
Daniel GLIDDON
Kin-Mei LEUNG
Cristian GRADINARU
Christopher Shepherd
Josefin-Beate Holz
Louis KAYITALIRE
Original Assignee
Invox Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invox Pharma Limited filed Critical Invox Pharma Limited
Publication of HK40071349A publication Critical patent/HK40071349A/en

Links

HK62022061147.4A 2019-05-14 2020-05-14 Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody HK40071349A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1906807.1 2019-05-14
GB1914040.9 2019-09-30
GB2000318.2 2020-01-09

Publications (1)

Publication Number Publication Date
HK40071349A true HK40071349A (en) 2022-11-04

Family

ID=

Similar Documents

Publication Publication Date Title
IL287979A (en) Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody
EP3916016A4 (en) Novel bispecific antibody molecule and bispecific antibody simultaneously combining pd-l1 and lag-3
EP3784214A4 (en) Liquid oral pharmaceutical dosage form
EP4098277A4 (en) Stable anti-pd-1 antibody pharmaceutical preparation
EP3768727A4 (en) Novel bispecific pd-1/lag-3 antibody molecules
EP3833691A4 (en) Human pd-l1 antibodies
HK40071349A (en) Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody
EP3647323A4 (en) Anti-gitr antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
IL281398A (en) Process for the preparation of a coated solid pharmaceutical dosage form
AU2020356348B2 (en) Pharmaceutical compounds
EP3980034A4 (en) T-cell depleting therapies
GB201914040D0 (en) Dosage regimes for the administration of lag-3/pd-l1 bispecific antibody
GB202000318D0 (en) Dosage regimes for the administration of LAG-3/PD-L1 bispecific antibody
GB201906807D0 (en) Dosages regimes for the administration of lag-3/pd-l1 bispectic antibody
EP4055061A4 (en) Dosage regimen for anti-egfrviii agents
HK40066344A (en) Ox40/pd-l1 bispecific antibody
HK40066344B (en) Ox40/pd-l1 bispecific antibody
HK40049719A (en) Dosing regimen for the treatment of pi3k related disorders
HK40113969A (en) Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
HK40108365A (en) Pharmaceutical composition comprising anti-pvrig/tigit bispecific antibody
HK40074182A (en) Dosing regimen for anti-dll3 agents
HK40115214A (en) Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
HK40076627A (en) Gel-chewable dosage form
HK40059540A (en) Pharmaceutical compositions comprising bispecific anti-cd37 antibodies
TWI900489B (en) Pharmaceutical compounds
点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载